Mercury Labs

Why is Mercury Laboratories Ltd falling/rising?

As of 11-Aug, Mercury Laboratories Ltd's stock price is stable at 818.90, with positive short-term performance trends and increased investor interest. However, long-term growth concerns and recent negative financial results may temper expectations.

As of 11-Aug, Mercury Laboratories Ltd's stock price is currently stable at 818.90, showing no change (0.00%). However, the stock has demonstrated positive performance trends in various time frames. Over the past week, it has risen by 0.79%, while in the last month, it has increased by 1.22%. Year-to-date, the stock has gained 0.95%, contrasting with a significant decline of 8.29% in the benchmark Sensex.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 3.66%, reaching an intraday high of Rs 823.05, which represents a 4.18% increase. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a positive trend in its price movement.<BR><BR>Investor participation has also increased, with delivery volume rising by 550.33% compared to the 5-day average, indicating growing interest among investors. The stock's liquidity is sufficient for trading, as it meets the criteria based on the average traded value.<BR><BR>Despite these positive indicators, the stock has faced challenges, including a decline in operating profit over the last five years at an annual rate of -10.57%. Furthermore, recent quarterly results showed a significant drop in net sales and operating profit margins, which could contribute to a cautious outlook among investors.<BR><BR>In summary, while Mercury Laboratories Ltd's stock is currently stable, it has shown positive short-term performance and increased investor interest, which are contributing factors to its rising trend in the near term. However, the long-term growth concerns and recent negative financial results may temper expectations moving forward.

Which are the latest news on Mercury Labs?

Are Mercury Laboratories Ltd latest results good or bad?

Mercury Laboratories Ltd's latest results are concerning, with Q1 FY27 revenue down 21.92% to ₹15.96 crores and net profit plummeting 69.07% to ₹0.30 crores, indicating severe operational challenges and a "Strong Sell" rating. The company is facing significant headwinds that may impact its profitability in the near term.

Mercury Laboratories Ltd's latest results are concerning and can be classified as bad. In Q1 FY27, the company experienced a significant decline in key financial metrics. Revenue fell by 21.92% sequentially to ₹15.96 crores, marking the lowest quarterly sales figure in recent history. Additionally, net profit dropped dramatically by 69.07% to just ₹0.30 crores, and operating profit margins compressed sharply to 7.46% from 13.01% year-on-year.<BR><BR>The overall financial performance indicates severe operational challenges, with both revenue and profit margins at record lows. The company's Mojo Score reflects this distress, landing at a low 20 out of 100, which corresponds to a "Strong Sell" rating. This suggests that the company is facing significant headwinds and may struggle to maintain profitability in the near term. <BR><BR>Given these factors, the results present a troubling picture for Mercury Laboratories, highlighting the need for urgent management attention to address these operational issues.

Should I buy, sell or hold Mercury Laboratories Ltd?

When is the next results date for Mercury Laboratories Ltd?

The next results date for Mercury Laboratories Ltd is 25 July 2026.

The next results date for Mercury Laboratories Ltd is scheduled for 25 July 2026.

How big is Mercury Labs?

As of 10th June, Mercury Laboratories Ltd has a market capitalization of 99.00 Cr, with recent net sales of 75.94 Cr and a net profit of 4.84 Cr. Shareholder's funds are 53.57 Cr, and total assets are valued at 74.24 Cr as of March 2025.

As of 10th June, Mercury Laboratories Ltd has a market capitalization of 99.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Mercury Laboratories Ltd reported Net Sales of 75.94 Cr and a Net Profit of 4.84 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 53.57 Cr and Total Assets were valued at 74.24 Cr.

Who are in the management team of Mercury Labs?

The management team of Mercury Labs includes Rajendra R Shah (Executive Director), Dilip R Shah (Non-Executive Director), Divyakant Ramniklal Zaveri (Chairman & Independent Director), Bharat Dhirajlal Mehta (Independent Non-Executive Director), Paresh Mistry (Non-Executive and Non-Independent Director), and Janki Shah (Non-Executive Director).

The management team of Mercury Labs includes the following individuals:<BR><BR>1. Rajendra R Shah - Executive Director, Managing Director, and Promoter<BR>2. Dilip R Shah - Non-Executive Director<BR>3. Divyakant Ramniklal Zaveri - Chairman & Independent Director<BR>4. Bharat Dhirajlal Mehta - Independent Non-Executive Director<BR>5. Paresh Mistry - Non-Executive and Non-Independent Director<BR>6. Janki Shah - Non-Executive Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Mercury Labs?

Peers of Mercury Labs include Concord Drugs, Pharmaids Pharma, Denis Chem Lab, Amwill Health, Makers Labs, Bharat Immunolog, Vaishali Pharma, Onyx Biotec, and Sotac Pharma. Mercury Labs has Below Average growth and management risk, with a 1-year return of -8.08%.

Peers: The peers of Mercury Labs are Concord Drugs, Pharmaids Pharma, Denis Chem Lab, Amwill Health, Makers Labs, Bharat Immunolog, Vaishali Pharma, Onyx Biotec, and Sotac Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab and Amwill Health, while Average management risk is found at Mercury Labs and Onyx Biotec. Below Average management risk is noted at Concord Drugs, Pharmaids Pharma, Makers Labs, Bharat Immunolog, Vaishali Pharma, and Sotac Pharma. Growth is rated as Excellent for Denis Chem Lab and Average for Amwill Health, while Below Average growth is seen at Mercury Labs, Concord Drugs, Pharmaids Pharma, Makers Labs, Bharat Immunolog, Vaishali Pharma, and Sotac Pharma. Capital Structure is Excellent at Denis Chem Lab and Amwill Health, Average at Onyx Biotec, and Below Average at Concord Drugs, Pharmaids Pharma, Mercury Labs, Makers Labs, Bharat Immunolog, Vaishali Pharma, and Sotac Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Concord Drugs at 161.37%, while Pharmaids Pharma has the lowest at -52.99%. Mercury Labs has a 1-year return of -8.08%, which is significantly higher than Pharmaids Pharma's return. Additionally, the six-month returns are negative for Pharmaids Pharma, Denis Chem Lab, Bharat Immunolog, and Mercury Labs.

What does Mercury Labs do?

Mercury Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, established in 1962, with recent quarterly net sales of 20 Cr and net profit of 1 Cr as of March 2026. Key financial metrics include a market cap of INR 99 Cr, P/E of 17.00, and a dividend yield of 0.45%.

Overview:<BR>Mercury Laboratories Ltd is engaged in the business of pharmaceutical items, medicinal drugs, and formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Mercury Laboratories Ltd began its business activities in 1962, transitioned to a Private Limited Company in February 1982, and later became a Limited Company in 1992 in Maharashtra. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 20 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 99 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 17.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.45%<BR>- Debt-Equity: 0.04<BR>- Return on Equity: 8.80%<BR>- Price to Book: 1.61<BR><BR>Contact Details:<BR>Address: 1st Floor 18 Shreeji Bhuwan 51, Princess Street Mangaladas Rd Mumbai Maharashtra : 400002<BR>Tel: 91-22-66372841<BR>Email: mllbrd@mwercurylabs.com<BR>Website: http://www.mercurylabs.com

How has been the historical performance of Mercury Labs?

Mercury Labs has experienced mixed financial performance, with net sales and operating income peaking at 75.56 Cr in Mar'24 before declining to 75.10 Cr in Mar'25, while profitability metrics such as profit after tax and earnings per share significantly decreased. Despite an increase in total assets, cash flow from operations fell sharply, indicating financial challenges.

Answer:<BR>The historical performance of Mercury Labs shows a mixed trend in financial metrics over the years.<BR><BR>Breakdown:<BR>Mercury Labs' net sales have fluctuated slightly, with a peak of 75.56 Cr in Mar'24, followed by a slight decline to 75.10 Cr in Mar'25. Total operating income mirrored this trend, reaching 75.56 Cr in Mar'24 before decreasing to 75.10 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 66.52 Cr in Mar'24 to 68.08 Cr in Mar'25, impacting the operating profit, which fell from 9.04 Cr to 7.02 Cr in the same period. Profit before tax also declined from 6.92 Cr in Mar'24 to 4.66 Cr in Mar'25, leading to a decrease in profit after tax from 5.65 Cr to 3.14 Cr. The earnings per share (EPS) dropped significantly from 47.08 in Mar'24 to 26.17 in Mar'25. On the balance sheet, total assets increased from 67.96 Cr in Mar'24 to 74.24 Cr in Mar'25, while total liabilities also rose from 67.96 Cr to 74.24 Cr, indicating a growing debt level. Cash flow from operating activities decreased from 8.00 Cr in Mar'24 to 4.00 Cr in Mar'25, contributing to a net cash outflow of 6.00 Cr in Mar'25, compared to a neutral cash flow in the previous year. Overall, while Mercury Labs has shown growth in total assets, its profitability and cash flow have faced challenges in the latest fiscal year.

Is Mercury Labs overvalued or undervalued?

As of November 12, 2025, Mercury Labs is considered undervalued with an attractive valuation grade, featuring a PE Ratio of 21.55, an EV to EBITDA of 12.70, and a PEG Ratio of 0.93, which are favorable compared to peers like Sun Pharma and Divi's Lab, despite recent underperformance relative to the Sensex.

As of 12 November 2025, Mercury Labs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 21.55, an EV to EBITDA of 12.70, and a PEG Ratio of 0.93, indicating a favorable valuation compared to its growth prospects.<BR><BR>In comparison with peers, Mercury Labs' PE Ratio is significantly lower than that of Sun Pharma, which stands at 35.94, and Divi's Lab at 69.64, both classified as expensive. Other peers such as Cipla and Dr. Reddy's Labs have PE Ratios of 22.56 and 17.77, respectively, but still fall short of Mercury Labs' attractive valuation. Despite recent underperformance relative to the Sensex over the past year, the company's strong ratios suggest it is positioned well for future growth.

What is the technical trend for Mercury Labs?

As of April 28, 2025, Mercury Labs exhibits a mildly bearish technical trend, influenced by mixed MACD signals and bearish daily moving averages.

As of 28 April 2025, the technical trend for Mercury Labs has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands and KST both reflect a mildly bearish outlook on the weekly and monthly time frames. The daily moving averages remain bearish, contributing to the overall mildly bearish sentiment. The Dow Theory suggests a mildly bearish trend on the weekly chart, with no clear trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and the bearish moving averages.

Who are the top shareholders of the Mercury Labs?

The top shareholder of Mercury Labs is Shah Dilip Ramanlal Huf, holding 25.88%, with no pledged promoter holdings. The highest public shareholder is Rajeshri Ketan Shah at 2.2%, while individual investors collectively own 16.66%.

The top shareholders of Mercury Labs include the promoters, with Shah Dilip Ramanlal Huf holding the highest stake at 25.88%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Rajeshri Ketan Shah, who owns 2.2% of the shares. Additionally, individual investors collectively hold 16.66% of the company.

Has Mercury Labs declared dividend?

Yes, Mercury Laboratories Ltd has declared a 35% dividend, amounting to 3.5 per share, with an ex-date of September 20, 2024. While recent returns have been negative, the company has shown substantial growth over the longer term, particularly in the last 3 to 5 years.

Mercury Laboratories Ltd has declared a 35% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 35%<BR>- Amount per share: 3.5<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.42%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.67%, with a dividend return of 0%, resulting in a total return of -15.67%.<BR><BR>Over the past year, the price return was -6.41%, the dividend return was 0.40%, leading to a total return of -6.01%.<BR><BR>In the 2-year period, the price return was 0.13%, the dividend return was 0.84%, resulting in a total return of 0.97%.<BR><BR>For the 3-year period, the price return was 81.36%, with a dividend return of 2.44%, culminating in a total return of 83.8%.<BR><BR>In the last 4 years, the price return was 13.56%, the dividend return was 1.70%, leading to a total return of 15.26%.<BR><BR>Over the past 5 years, the price return was 85.27%, with a dividend return of 5.04%, resulting in a total return of 90.31%.<BR><BR>Overall, Mercury Laboratories Ltd has declared a significant dividend, and while recent returns over shorter periods have been negative, longer-term returns show substantial growth, particularly in the last 3 to 5 years.